Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.

Also called NCT03271879

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03271879
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03271879. Randomized; double masking; primary purpose treatment. Start 2018-02-15 (anticipated); primary completion 2019-09-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
Acronym
ERA-HF
Condition
Heart Failure
Condition
Diabetes Mellitus
Condition
Arrythmia
Intervention (Drug)
Empagliflozin at a dose of 10 mg/day
Lead sponsor
Rambam Health Care Campus (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct03271879
Content hash
327c6a7c38c931385a4a0a1440ae3e1c68121866dad53e1c0278abb60484e41c